Worldwide Single Cell Analysis (SCA) Market Forecasted to Grow at 10% p.a., Reaching $2.1B by 2029 – Market Report by DeciBio Consulting LLC

LOS ANGELES--(BUSINESS WIRE)--According to a comprehensive market report authored by DeciBio Consulting LLC, “Single-Cell Analysis (SCA): Market Size, Segmentation, Growth, Competition, and Trends (2024-2029),” the global single-cell analysis market is predicted to reach $2.1B by 2029. This growth will be driven by broader adoption across both biopharma and academia, falling costs enabling higher throughput experiments, and increasing use of newer assays, particularly those supporting FFPE- and multomics-based analysis.

This sixth edition of DeciBio’s single-cell analysis (SCA) report takes an updated and comprehensive look at the SCA landscape. Informed by a combination of primary research from 100+ stakeholders, secondary research, and proprietary DeciBio databases and tools, this report provides a quantitative and qualitative assessment of the key SCA market segments.

SCA is an increasingly established approach, as it offers the ability to assess the biology of individual cells, as compared to bulk analysis approaches, which only provide one readout for an entire cell population. SCA approaches are uniquely positioned to revolutionize biology by shedding light on cellular heterogeneity, which has important implications across biology and diseases. Studies thus far have already provided important insights, and recent technical advances continue to facilitate growth in this field.

Report Details
Research Methods	Secondary research: analysis of quarterly and annual reports, earnings call transcripts, congress abstracts, company websites Primary research: Interviews with 29 SCA stakeholders and a survey with 80 SCA stakeholders across the U.S., EU, and ROW in academia, biopharma, and CROs Proprietary databases / analysis: use of internal databases and tools (e.g., TheraTrack, Dexter expert network)
2029 Market Size	$2.1 billion
CAGR (2024-2029)	10%
Base Year	2024
Forecast Period	2024-2029
Market / Forecast Currency	USD
Report Coverage	Market size, segmentation, and forecast; key market players and trends; assays and technologies; market drivers and moderators; competitive analysis
Segments Covered	Customer (academia, biopharma, applied markets, clinical) Workflow (tissue dissociation, sample preparation, downstream analysis) Analyte (RNA, DNA, epigenetic, protein, multiomic, other) Field-of-Study (oncology, immunology, microbiology, basic cell biology, stem cell biology, neurology, other) Product type (instruments, reagents, services, other) Geography (U.S., Europe, China, Asia Pacific, Rest-of-the-World)

Learn more about DeciBio’s Single Cell-Analysis Market Report Sixth Edition: www.decibio.com/market-reports/single-cell-genomics-market-assessment-report

Single-Cell Analysis Companies Profiled:

• 10x Genomics
• BD
• Bruker
• Illumina
• MGI Tech
• Mission Bio
• Parse Biosciences
• Singleron
• Scale Biosciences
• Takara Bio

Market Drivers:

Though growth in the market has slowed down in the past two years, a number of factors will support growth through 2029. A growing acceptance of the maturity of SCA technology drives adoption among new users in academia, as well as expanded use within biopharma. The decreasing costs of assay and sequencing allow for higher throughput experiments, expanding the scope and scale of single cell studies. Additionally, adoption and expansion in the use of FFPE-based assays continues within biopharma, supporting discovery work with tissue samples previously inaccessible for SCA. The report also underscores the importance of advances in multiomic-based single cell analysis as an avenue for market growth, as multiomic assays combining epigenetic or proteomic analysis with RNA sequencing unlock deeper insights into cellular functionality and behavior.

Market Moderators:

The 6th Edition also highlights key moderators likely to impact growth in the SCA market over the forecasted period. The rise of spatial-omics technologies, which are beginning to offer single-cell resolution, is increasingly competing for research budgets traditionally allocated to single-cell methods. Furthermore, the emergence of instrument-free approaches (e.g., Parse, Illumina / Fluent, Scale) is increasing competition among SCA vendors and putting downward pressure on reagent and instrument pricing. The report also notes that the lack of clear clinical applications uniquely addressable by single cell analysis is currently limiting its use primarily to R&D and early-stage trials.

About DeciBio:

DeciBio Consulting (www.decibio.com) is the leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating innovation in precision medicine.

Headquartered in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.